Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib and Atezolizumab in Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT05538091Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Aug 2031
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib, atezolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Started May 2023; status: recruiting.
02
Drugs
vismodegibatezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05538091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538091.